Sesen Bio logo
Sesen Bio SESN

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Sesen Bio Income Statement 2011-2026 | SESN

Annual Income Statement Sesen Bio

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

26.1 M 21.1 M 1.23 M 135 M 202 M 85.1 M 43.9 M 27.1 M 44.1 M 6.08 M 170 M - - -

Shares

41.5 M 33.5 M 2.13 M 182 M 118 M 90.9 M 61.8 M 26.1 M 21.1 M 19 M 14.6 M - - -

Historical Prices

0.63 0.63 0.58 0.741 1.71 0.95 0.729 1.04 2.14 0.32 11.6 - - -

Net Income

-60.5 M -86.9 M -61.2 M -336 K -22.4 M -108 M -33.7 M -29 M 1.89 M -33.5 M -34.2 M -18 M -19.7 M -12.8 M

Revenue

19.6 M 14.9 M 9.8 M 26.5 M 11.2 M - - 425 K 30 M 990 K 2.24 M 1.33 M - -

Gross Profit

- - - - - - - - - 990 K - 1.33 M - -

Operating Income

-62.2 M -88.7 M -56.2 M -8.55 M -21.1 M -108 M -34.5 M -29.3 M 2.87 M -35.2 M -32.9 M -16.5 M -19.5 M -

Interest Expense

- - - -77 K -99 K 991 K 807 K 226 K -723 K 3.14 M -849 K -147 K -13 K -

EBITDA

-58.8 M -85.9 M -54.3 M -8.46 M -21 M -36.7 M -25.5 M -19.9 M 1.94 M -34.8 M -32.5 M -16 M -19 M -12.3 M

Operating Expenses

81.8 M 104 M 66 M 35.1 M 32.3 M 36.9 M 25.7 M 20.6 M 28.2 M 36.2 M 35.2 M 17.8 M - -

General and Administrative Expenses

22.1 M 29.5 M 9.38 M 29.4 M 14.3 M 12.2 M 11.6 M 8.07 M 14.7 M 9.85 M 8.47 M 4.02 M 4.21 M 3.27 M

All numbers in USD currency

Quarterly Income Statement Sesen Bio

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

41.8 M 41.8 M 41.8 M 41.8 M 41.6 M 41.5 M 40.9 M 40.6 M 40.3 M 40.3 M 12.8 M 2.22 M 2.19 M 2.06 M 2.06 M 199 M 197 M 175 M 157 M 140 M 118 M 113 M 110 M 107 M 101 M 80.7 M 77.5 M 77.5 M 77 M 56.4 M 35.7 M 34.7 M 24.7 M 24.7 M 24.6 M 24.5 M 20.5 M 19.9 M 19.6 M 19.6 M 19.3 M 19.1 M 18 M 17.9 M 16.1 M 16.1 M 9.64 M 1.64 M 1.39 M 1.32 M 1.25 M - - - - - - - -

Net Income

44.7 M -9.77 M -9.27 M - -12.7 M -11.2 M -19 M - -21.4 M -19.9 M -24.6 M - -18.3 M -14.8 M -11.3 M - 71.7 M -25.4 M -55.5 M - -22.6 M -26.3 M 41.6 M -33.6 M -13.1 M -54.3 M -6.48 M -6.76 M -14 M -8.96 M -3.96 M -6.55 M -9.1 M -7.32 M -6.06 M -3.53 M 19.5 M -6.49 M -7.57 M -10.3 M -9.69 M -6.91 M -6.52 M -8.14 M -10.7 M -8.12 M -7.22 M -5.07 M -3.81 M -3.63 M -5.51 M - - - - - - - -

Revenue

45.3 M - 3.7 M - 3.4 M 9.2 M 3.4 M - 3.8 M 3.6 M 3.24 M - 2.58 M 2.7 M 822 K - - 2.23 M 4.31 M - 11.2 M - - - - - - - - - - - - - 425 K 825 K 28.6 M 277 K 229 K 565 K 67 K 114 K 244 K 375 K 539 K 761 K 568 K 510 K 622 K 202 K - - - - - - - - -

Operating Income

43.8 M -5.78 M -9.33 M - -13.1 M -11.7 M -19.5 M - -22.3 M -21 M -23 M - -16.8 M -13.9 M -10.2 M - 63.1 M -25.4 M -55.2 M - -21.5 M -26.4 M 41.4 M -33.7 M -13.5 M -54.6 M -6.74 M -7.07 M -14.4 M -9.03 M -4.01 M -6.59 M -9.15 M -7.35 M -6.16 M -3.62 M 19.5 M -6.49 M -6.55 M -9.84 M -9.36 M -8.4 M -7.6 M -7.1 M -10.6 M -8.04 M -7.19 M -4.12 M -3.54 M -3.38 M -5.44 M - - - - - - - -

Interest Expense

583 K 470 K - - 442 K 508 K - - - - - - 676 K 162 K 28 K - 1 K -43 K -3 K - -1 K 16 K 179 K - 319 K 226 K 261 K - 382 K 72 K 44 K - 45 K 34 K 101 K - -43 K 1 K 138 K - 73 K 1.83 M 1.31 M - 2 K 3 K 51 K - 16 K -114 K 2 K - - - - - - - -

EBITDA

- - -8.67 M - - - -17.8 M - - - -22.3 M - -16.7 M -13.9 M -9.94 M - 63.2 M -25.3 M -55.2 M - -21.4 M -26.3 M 41.4 M -33.7 M -13.3 M -54.5 M -6.69 M -7.07 M -14.2 M -8.93 M -3.96 M -6.59 M -8.93 M -7.18 M -6.08 M -3.62 M 19.6 M -6.4 M -6.5 M -9.84 M -9.07 M -8.21 M -7.5 M -7.1 M -10.3 M -7.84 M -7.09 M -4.12 M -3.2 M -3.16 M -5.32 M - - - - - - - -

Operating Expenses

1.44 M 5.78 M 13.1 M - 16.5 M 20.9 M 22.9 M - 26.2 M 24.5 M 26.2 M - 19.3 M 16.6 M 11 M - -63.1 M 27.6 M 59.5 M - 32.7 M 26.4 M -41.4 M 33.7 M 13.5 M 54.6 M 6.74 M 7.07 M 14.4 M 9.03 M 4.01 M 6.59 M 9.15 M 7.35 M 6.59 M 4.45 M 9.12 M 6.77 M 6.78 M 10.4 M 9.43 M 8.52 M 7.84 M 7.47 M 11.1 M 8.81 M 7.76 M 4.63 M 4.16 M 3.58 M 5.44 M - - - - - - - -

General and Administrative Expenses

1.24 M 3.35 M 3.91 M - 5.2 M 5.56 M 5.44 M - 6.62 M 6.01 M 9.57 M - 3.77 M 2.42 M 2.21 M - 8.7 M 6.8 M 5.29 M - 4.12 M 3.32 M 3.45 M - 3.24 M 2.62 M 3.06 M - 3.82 M 2.35 M 1.95 M - 1.63 M 2.24 M 2.21 M - 6.37 M 3.47 M 2.15 M - 2.68 M 2.25 M 2.6 M - 2.27 M 2.05 M 1.94 M - 786 K 881 K 939 K - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Sesen Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.5 1.86 % $ 3.73 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 327.16 2.39 % $ 42.9 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Amgen Amgen
AMGN
$ 349.22 2.71 % $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.4 -0.87 % $ 954 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.18 1.33 % $ 447 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.57 5.59 % $ 3.13 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.48 8.46 % $ 394 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.85 2.41 % $ 9.26 B australiaAustralia
BioNTech SE BioNTech SE
BNTX
$ 91.76 2.39 % $ 27.2 B germanyGermany
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.71 5.51 % $ 17 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.06 0.99 % $ 6.66 B israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
$ 3.06 -0.33 % $ 307 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.9 2.99 % $ 362 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.7 1.8 % $ 199 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.36 0.28 % $ 4.12 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 25.57 2.3 % $ 3.13 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.81 2.18 % $ 7.33 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA